

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Completes If Known	
				Application Number	10/598,449
				Filing Date	August 30, 2006
				First Named Inventor	Hamed Aissaoui
				Art Unit	1625
				Examiner Name	Zinna Northington Davis
Sheet	1	of	3	Attorney Docket No: AC-26-US	

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T*
		Official Note 34103 of Instituto Mexicano de la Propiedad Industrial, dated April 28, 2009 in Mexican Patent No. 269553, PA/a/2006/009833, foreign counterpart to present application.	N/A	ACTELION PHARMACEUTICAL LTD	✓
		Response of June 25, 2009 to Official Note 34103 of Instituto Mexicano de la Propiedad Industrial, dated April 28, 2009 in Mexican Patent No. 269553, PA/a/2006/009833, foreign counterpart to present application.	N/A	ACTELION PHARMACEUTICAL LTD	✓

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T*
		SAKURAI T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature Reviews. Neuroscience, Vol 8; March 2007.			
		SUTCLIFFE J.G. & DE LECEA L. The hypocretins: setting the arousal threshold. Nature Reviews. Neuroscience 3, 339-49; 2002.			
		BRISBARE-ROCH C, FELETTI L, KOBERSTEIN R, NAYLER O, JENCK F. Transient orexin receptor blockade induces sleep without cataplexy in rats, Nature Clinical Practice Neurology, May 2007, Vol. 3, No. 5, pg. 245.			
		JENCK F, FISCHER C, QIU C, HESS P, KOBERSTEIN R, BRISBARE-ROCH C Somnolence induced by pharmacological blockade of both orexin OX1 and OX2 receptors in dogs, Sleep and Biological rhythms 2007,5, (S1), A79 Poster 271 at the World Sleep Congress, Cairns, September 2007.			

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; font-weight: normal;">Complete if Known</th> </tr> <tr> <td style="width: 35%;"><b>Application Number</b></td> <td>10/598,449</td> </tr> <tr> <td><b>Filing Date</b></td> <td>August 30, 2006</td> </tr> <tr> <td><b>First Named Inventor</b></td> <td>Hamed Aissaoui</td> </tr> <tr> <td><b>Art Unit</b></td> <td>1625</td> </tr> <tr> <td><b>Examiner Name</b></td> <td>Zinna Northington Davis</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> </table>	Complete if Known		<b>Application Number</b>	10/598,449	<b>Filing Date</b>	August 30, 2006	<b>First Named Inventor</b>	Hamed Aissaoui	<b>Art Unit</b>	1625	<b>Examiner Name</b>	Zinna Northington Davis		
Complete if Known																		
<b>Application Number</b>	10/598,449																	
<b>Filing Date</b>	August 30, 2006																	
<b>First Named Inventor</b>	Hamed Aissaoui																	
<b>Art Unit</b>	1625																	
<b>Examiner Name</b>	Zinna Northington Davis																	
Sheet	2	of	3	Attorney Docket No: AC-26-US														

		HOEVER P, DE HAAS S, WINKLER J, CAVALLARO M, VAN GERVEN J, DINGEMANSE J, Entry-into-humans study with almorexant (ACT-078573), a dual orexin receptor antagonist: tolerability, safety, and pharmacokinetics, Sleep and Biological rhythms 2007,5 (S1): A131, Poster 444 at the World Sleep Congress, Cairns, September 2007.	
		HOEVER P, DE HAAS S, CHIOSSI E, VAN GERVEN J, DINGEMANSE J, Entry-into-humans study with almorexant (ACT-078573), a dual orexin receptor antagonist: pharmacodynamics, Sleep and Biological rhythms 2007,5 (S1): A131, Poster 443 at the World Sleep Congress, Cairns, September 2007.	
		DINGEMANSE J, DORFFNER G, HAJAK G, BENES H, DANKER-HOPFE H, POLO O, SALETU B, BARBANOJ MJ, PILLAR G, PENZEL T, CHIOSSI E, HOEVER P, Proof-of-concept study in primary insomnia patients with almorexant (ACT-078573), a dual orexin receptor antagonist, Sleep and Biological rhythms 2007,5: A194, Poster 653 at the World Sleep Congress, Cairns, September 2007.	
		BRISBARE-ROCH C, DINGEMANSE J, KOBERSTEIN R, HOEVER P, AISSAOUI H, FLORES S, MUELLER C, NAYLER O, VANGERVEN J, DEHAAS S, HESS P, QIU C, BUCHMANN S, SCHERZ M, WELLER T, FISCHLI W, CLOZEL M & JENCK F, Promotion of sleep by targeting the orexin system in rats, dogs and humans, Nature Medicine, 13: 150-155, 2007	
		JENCKF, BRISBARE-ROCH C, FLORES S, KOBERSTEIN R, NAYLER O, DINGEMANSE J, CLOZEL M, Correspondence on "promotion of sleep by targeting the orexin system in rats, dogs and humans", Nature Medicine, 13: 525-526, 2007.	
		BRISBARE-ROCH C, CLOZEL M, JENCK F, Effects of repeated oral administration of the orexin receptor antagonist almorexant in male rats and dogs, Sleep 2008,31: A38 Poster 0118 at the US Associated Professional Sleep Societies meeting, Baltimore, June 2008.	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: right; font-weight: normal; font-size: small;">Complete If Known</th> </tr> <tr> <td style="width: 30%;"><b>Application Number</b></td> <td>10/598,449</td> </tr> <tr> <td><b>Filing Date</b></td> <td>August 30, 2006</td> </tr> <tr> <td><b>First Named Inventor</b></td> <td>Hamed Aissaoui</td> </tr> <tr> <td><b>Art Unit</b></td> <td>1625</td> </tr> <tr> <td><b>Examiner Name</b></td> <td>Zinna Northington Davis</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> </table>		Complete If Known		<b>Application Number</b>	10/598,449	<b>Filing Date</b>	August 30, 2006	<b>First Named Inventor</b>	Hamed Aissaoui	<b>Art Unit</b>	1625	<b>Examiner Name</b>	Zinna Northington Davis		
Complete If Known																			
<b>Application Number</b>	10/598,449																		
<b>Filing Date</b>	August 30, 2006																		
<b>First Named Inventor</b>	Hamed Aissaoui																		
<b>Art Unit</b>	1625																		
<b>Examiner Name</b>	Zinna Northington Davis																		
Sheet	3	of	3	Attorney Docket No: AC-26-US															

		HOEVER P, DE HAAS S, CHIOSSI E, VAN GERVEN J, DINGEMANSE J, Multiple-dose pharmacokinetics, pharmacodynamics, safety, and tolerability of the orexin receptor antagonist almorexant in healthy subjects. Sleep 2008;31: A38 Poster 0116 at the US Associated Professional Sleep Societies meeting, Baltimore, June 2008.	
		JENCK F., BRISBARE-ROCH C, AISSAOUI H, KOBERSTEIN R, Promotion of sleep through an orally available hypocretin/orexin antagonist in rats, dogs and humans, Eur Neuropsychopharm 2008;18 (Suppl4): S158, Lecture at the European College of Neuropsychopharmacology (ECNP) meeting, Barcelona, September 2008.	
		FURLONG TM, DANIEL M. L.VIANNA, LU LIU AND PASCAL CARRIVE, Extramural: Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal European Journal of Neuroscience, 2009, AOP: Oct 7, 2009	
		HOCH M, HOEVER P, HASCHKE M, KRÄHENBÜHL S, ALESSI F, DINGEMANSE J, Biocomparison of two formulations of almorexant, a dual orexin receptor antagonist, including investigation of food effect, Poster at American College of Clinical Pharmacology, 38th Annual Meeting, San Antonio, Texas, September 13–15, 2009	
		JAE-EUNKANG, MIRANDA M. LIM, RANDALL J. BATEMAN, JAMES J. LEE, LIAM P.SMYTH, JOHN R. CIRrito, NOBUHIROFUJIKI, SEIJI NISHINO, DAVID M. HOLTZMAN, Extramural: Amyloid-βDynamics Are Regulated by Orexin and the Sleep-Wake Cycle, ScienceExpress, 24 September 2009	

EXAMINER

DATE CONSIDERED